Civica
Civica is a nonprofit pharmaceutical company that supplies 70+ essential generic sterile injectable medications to 1,400+ U.S. hospitals through 60 health system members, and through its CivicaScript subsidiary distributes affordable outpatient generics and biosimilars to health plans, PBMs, and retail pharmacies.
- Company typePrivate
- Founded2018
- HeadquartersLehi, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Civica does
Civica is a Delaware-incorporated nonprofit pharmaceutical company founded in 2018 and headquartered in Lehi, Utah, created by leading U.S. health systems and philanthropies to address chronic generic drug shortages and predatory pricing. The company supplies more than 70 essential sterile injectable generic medications to over 1,400 hospitals through 60 health system members that collectively represent more than 30% of U.S. licensed hospital beds, supporting care for approximately 95 million patients. Civica's core technology is a U.S.-based manufacturing capability centered on the $124.5 million, 140,000+ square-foot Petersburg, Virginia fill-finish facility equipped with Groninger and SKAN isolator technology, disposable systems, and three production lines (vials, pre-filled syringes, pre-filled pen cartridges) capable of producing over 200 million units annually.
The business operates on a cost-plus pricing model with six months of safety stock and direct contracting that bypasses traditional rebate and middleman structures. Civica monetizes through hospital membership contracts (Civica Rx), a Federal Supply Schedule contract with the U.S. Department of Veterans Affairs, and a consumer/outpatient arm (CivicaScript) that distributes affordable generics and biosimilars to health plans, PBMs, and retail pharmacies—including insulin glargine-yfgn at $45 per five-pen box and ustekinumab-aauz biosimilar at $575-$985 per 12-week supply. The Civica Foundation, a 501(c)(3) subsidiary, channels philanthropic support for programs such as affordable insulin and the Rural Hospital Program. Partnerships span the biopharma ecosystem: Biocon Biologics for insulin manufacturing, Phlow Corp. and VCU's Medicines for All Institute for end-to-end domestic production, AmerisourceBergen for distribution, CalRx for California's state-branded insulin initiative, and Breakthrough T1D plus the Helmsley Charitable Trust for funding. Civica is governed by hospital systems, payer representatives, and philanthropic organizations rather than equity investors, with leadership led since June 2022 by CEO Ned McCoy.
Civica firmographics
Firmographics- Name
- Civica
- Legal name
- Civica, Inc.
- Website
- https://civicarx.org
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Civica is a nonprofit pharmaceutical company that supplies 70+ essential generic sterile injectable medications to 1,400+ U.S. hospitals through 60 health system members, and through its CivicaScript subsidiary distributes affordable outpatient generics and biosimilars to health plans, PBMs, and retail pharmacies.
- Ownership category
- akta.pro rank
Civica industry classification
Industry- Product category
- Generic Pharmaceuticals
- NAICS
- Voluntary Health Organizations (813212), Civic and Social Organizations (81341), Social Advocacy Organizations (8133)
- SIC
- Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- akta.pro primary industry
- Generic Hospital & Institutional Products (HLAIABAL)
- akta.pro secondary industry
- Hospitals, Clinics & Charitable Healthcare Providers (BPAGACAB)
Keywords
Where Civica is headquartered
LocationHeadquarters
- HQ city
- Lehi
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
Civica business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Supply Chain, Personnel, Technology or R&D, Infrastructure, Marketing or Sales
Revenue model
- Hospital Membership and Drug Sales: Civica sells essential generic medications directly to member hospitals through long-term contracts. Hospitals pay membership fees and purchase medications at cost-plus pricing without hidden rebates or unfair markups.
- Rural Hospital Membership Fees (Covered by Grant): For rural hospitals in the Civica Rural Hospital Program, per-bed membership fees are covered by the $3.2M Helmsley Charitable Trust grant. Civica waives annual purchase commitments for these hospitals.
- Federal Government Contracts: Civica supplies essential generic medications to the U.S. Department of Veterans Affairs through a Federal Supply Schedule (FSS) contract, available to VA medical centers, outpatient clinics, and other federal agencies including the Department of Defense.
- CivicaScript Outpatient Medications: CivicaScript sells affordable generic medicines and biosimilars to health plans, pharmacy benefit managers, and retail pharmacies. Products include insulin glargine at $45/box and ustekinumab biosimilar at $575-$985 per 12-week supply.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Insulin Glargine-yfgn prefilled pens - lowest list price in long-acting insulin market |
| Unit Pricing | Pay-as-you-go | Insulin vials - recommended maximum consumer price |
| Unit Pricing | Pay-as-you-go | Ustekinumab-aauz (biosimilar to Stelara) - 12-week supply |
| Subscription | Annual | Rural Hospital Program - membership fees covered by grant |
Go-to-market motion1 record
Distribution channels4 records
Marketing channels5 records
Civica product offering
Product offeringCore offering
Civica is a nonprofit pharmaceutical company that manufactures and distributes essential sterile injectable generic medications to over 1,400 U.S. member hospitals through long-term contracts, and through its CivicaScript subsidiary provides affordable outpatient generics and biosimilars (including insulin glargine and ustekinumab biosimilars) to health plans, PBMs, and pharmacies at transparent maximum retail prices. The company operates its own U.S. manufacturing facility in Petersburg, Virginia and maintains six months of safety stock on essential medicines to prevent shortages and price gouging.
Product overview
Civica operates as a nonprofit pharmaceutical company with two main operating units: Civica Rx provides essential generic sterile injectable medications to member hospitals, while CivicaScript serves as the outpatient/retail arm offering affordable generic medicines and biosimilars. The company also includes Civica Foundation for philanthropy. The portfolio includes hospital-administered generics (over 70 essential medicines), biosimilar insulins (insulin glargine-yfgn), and biosimilars for chronic inflammatory conditions (ustekinumab-aauz). Civica focuses on addressing drug shortages and high prices through a mission-driven nonprofit model.
Differentiator
Problem solved
Functional benefit
Products and services
- Civica Rx Essential Hospital Generic Injectables Over 70 essential generic sterile injectable medications supplied directly to over 1,400 U.S. member hospitals through long-term market-stabilizing contracts at cost-plus pricing with six months of safety stock maintained.
- CivicaScript Outpatient Generics and Biosimilars Outpatient/retail arm of Civica selling affordable generic medicines and biosimilars to health plans, pharmacy benefit managers, and retail pharmacies at transparent Maximum Retail Prices.
- Insulin Glargine-yfgn Biosimilar long-acting insulin glargine indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus; interchangeable with Lantus; available in prefilled pens distributed nationwide through pharmacies.
- Ustekinumab-aauz Biosimilar ustekinumab product indicated for treatment of chronic inflammatory conditions including plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis; interchangeable with Stelara.
Quantifiable outcome
- Saved patients and payers more than $16 million in 2025; nearly $44 million total savings since 2022
- +5 more outcomes
Companies that use Civica
Customer profileNamed customers14 records
Segments5 records
Ideal customer profiles4 records
Civica technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Civica partnerships and signals
Strategic signalPartnerships
18 partnerships are on record, tiered core, major and minor.
- Biocon BiologicscoreBiocon Biologics expanded collaboration with Civica to manufacture and supply insulin glargine, which Civica markets under its own label. The partnership improves access and affordability for U.S. patients with diabetes, with Biocon manufacturing under its existing U.S. marketing approval and Civica distributing nationally (as CalRx in California).
- California / CalRxcoreCalifornia's CalRx biosimilar insulin initiative selected Civica as manufacturing partner. Civica insulin glargine will carry the CalRx brand in California pharmacies. This partnership aims to reduce insulin costs for California residents and influence market prices.
- Phlow Corp.corePartnership with Phlow Corp. as part of a U.S. government-funded effort to manufacture essential medications from beginning to end, including APIs and finished dosage forms. Phlow leads the partnership which also includes VCU's Medicines for All Institute and AMPAC Fine Chemicals. Phlow executed a $354 million BARDA contract for manufacturing essential medications.
- Virginia Commonwealth University / Medicines for All InstitutecorePartnership with VCU's Medicines for All Institute as part of the public-private manufacturing consortium aimed at creating a resilient regional biopharmaceutical ecosystem in Virginia.
- AmerisourceBergenmajorExclusive distribution partnership established with AmerisourceBergen for distributing Civica products.
- Groninger and SKANmajorEquipment and technology partners for Civica's Virginia manufacturing facility. Groninger and SKAN provide world-class fill-finish manufacturing technology for the sterile injectable facility.
- Blue Cross Blue Shield Association (BCBSA)coreBCBSA is a founding member and board participant in Civica. BCBSA and Blue Cross and Blue Shield Plans partner with CivicaScript through InnovateRx LLC (founded by 19 BCBS plans) to provide affordable medications and insulin at prices people can afford.
- Blue Cross of IdahomajorBlue Cross of Idaho represents the payer community on Civica's Board of Directors and works on pharmacy innovation initiatives.
- U.S. Department of Veterans AffairsmajorCivica awarded Federal Supply Schedule (FSS) contract by VA to supply essential generic medications via Pharmaceutical Prime Vendor program. Products available to VA medical centers, outpatient clinics, and other federal agencies including DoD.
- GeneSys BiologicsmajorPartnership with GeneSys Biologics for affordable insulin development, orchestrated by Ned McCoy to bring Civica biosimilar insulins to market.
- Thermo FisherminorContract manufacturing organization working with Civica to produce medications under Civica's ANDAs.
- HighmarkmajorHighmark is a founding member of CivicaScript and partners with Civica to provide lower-cost generic medications to members. Highmark members saved over $6 million on abiraterone acetate. Highmark also participates in CivicaRx insulin initiative.
- Virginia Talent Accelerator ProgrammajorVirginia Talent Accelerator Program partnered with Civica Rx to provide customized workforce training for approximately 300 positions at the Petersburg facility, in conjunction with Virginia Community College System.
- Inova HealthminorNew member joined Civica in 2025, representing healthcare system with significant hospital beds.
- Alaskan Native Tribal Health Consortium (ANTHC)minorNew member joined Civica in 2025, focused on tribal health services.
- AllinaminorNew member joined Civica in 2025, representing Minnesota-based health system.
- AveraminorNew member joined Civica in 2025, representing South Dakota-based health system.
- Dartmouth Mary Hitchcock MemorialminorNew member joined Civica in 2025, representing Dartmouth Health system.
Scale indicators21 records
Recent moves9 records
Expansion highlights7 records
Civica competitors and assessment
Company assessmentBroad incumbents
- Sandoz (Novartis): World's largest generic pharmaceutical company with a substantial US sterile injectables and biosimilars franchise. Competes with both Civica Rx and CivicaScript (especially on biosimilars like ustekinumab and insulin glargine).
- Fresenius Kabi: Large global manufacturer of generic injectable pharmaceuticals and IV drugs supplied to US hospitals. Directly overlaps with Civica's sterile injectable portfolio and competes for the same hospital pharmacy contracts.
- Teva Pharmaceuticals: Largest generic drug manufacturer globally with significant US presence in sterile injectables, oral solids, and biosimilars. Direct competitor to Civica in essential medicines and to CivicaScript in outpatient generics.
- Hikma Pharmaceuticals: Global generic injectables manufacturer with a major US hospital injectables franchise. Comparable product overlap with Civica's hospital sterile injectable portfolio, though Hikma is a publicly traded for-profit manufacturer at much larger scale.
- Pfizer (Hospira): Through its Hospira acquisition, Pfizer operates one of the largest sterile injectable manufacturing networks in the US. Competes head-to-head with Civica in hospital injectables and is also a critical supply chain partner referenced in industry shortage dynamics.
Direct peers
- Apotex: Large Canadian-headquartered generic pharmaceutical manufacturer with significant US operations. Comparable in offering affordable generic medicines including injectables and oral solids to health systems.
- Phlow Corp. US-based public-private pharmaceutical manufacturer focused on essential medicines and API production, partnered with Civica in a $354M BARDA-funded consortium. Most directly comparable given shared mission of domestic essential-medicine manufacturing.
- Biocon Biologics: India-based biosimilars manufacturer that is a critical OEM partner to Civica for insulin glargine and competes in the same biosimilars end markets. Closely tied commercially through CivicaScript distribution.
- Amphastar Pharmaceuticals: US-based specialty injectable pharmaceutical company focusing on generic and branded injectables, including difficult-to-formulate products. Direct competitor in hospital injectable generics.
- Lannett (Bausch Health): US-focused generic pharmaceutical manufacturer producing a portfolio of hospital and retail generics, including sterile injectables. Comparable scale and channel mix to Civica.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Civica social profiles
Digital presenceCivica financial estimates
Financial estimateRevenue estimate
Valuation estimate
Civica leadership team
Management profileNumber of profiles
Profiles10 records
Civica subsidiaries and ownership
Company hierarchySubsidiaries2 records
Civica funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Civica M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Civica
What does Civica do?
Civica is a nonprofit pharmaceutical company that manufactures and distributes essential sterile injectable generic medications to over 1,400 U.S. member hospitals through long-term contracts, and through its CivicaScript subsidiary provides affordable outpatient generics and biosimilars (including insulin glargine and ustekinumab biosimilars) to health plans, PBMs, and pharmacies at transparent maximum retail prices. The company operates its own U.S. manufacturing facility in Petersburg, Virginia and maintains six months of safety stock on essential medicines to prevent shortages and price gouging.
Is Civica a public or private company?
Civica is a private company. It is classified as nonprofit foundation owned and is currently operating.
When was Civica founded?
Civica was founded in 2018. It employs 1 to 10 people.
Where is Civica based?
Civica is headquartered in Lehi, United States, in the North America region.
How does Civica make money?
Four revenue lines are on record. Hospital Membership and Drug Sales are the primary driver. The others are rural Hospital Membership Fees (Covered by Grant), federal Government Contracts and civicaScript Outpatient Medications.
Who are Civica's main competitors?
Broad incumbents on record are Sandoz (Novartis), Fresenius Kabi, Teva Pharmaceuticals, Hikma Pharmaceuticals and Pfizer (Hospira). Direct peers are Apotex, Phlow Corp., Biocon Biologics, Amphastar Pharmaceuticals and Lannett (Bausch Health).
Does Civica have an API?
No public API is recorded for Civica.
What industry is Civica in?
Civica's product category is Generic Pharmaceuticals. Its primary akta.pro industry code is HLAIABAL, Generic Hospital & Institutional Products, with a secondary code of BPAGACAB, Hospitals, Clinics & Charitable Healthcare Providers. Its NAICS code is 813212 and its SIC code is 2834.